The following represents disclosure information provided by authors of this abstract. The Gastrointestinal Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of combined chemotherapy with irinotecan, S-1, and bevacizumab (IRIS/Bev) in patients with metastatic colorectal cancer (mCRC): Final analysis—Hokkaido Gastrointestinal Cancer Study Group (HGCSG) trial.
Satoshi Yuki
No relevant relationships to disclose
Yoshito Komatsu
Research Funding - Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; Novartis; Pfizer; Taiho Pharmaceutical; Yakult Honsha
Hiraku Fukushima
No relevant relationships to disclose
Takahide Sasaki
No relevant relationships to disclose
Toraji Amano
No relevant relationships to disclose
Takuto Miyagishima
No relevant relationships to disclose
Kazuteru Hatanaka
No relevant relationships to disclose
Michio Nakamura
No relevant relationships to disclose
Miki Tateyama
No relevant relationships to disclose
Yuh Sakata
Honoraria - Bristol-Myers Squibb; Daiichi Sankyo; Merck Serono; Otsuka; Taiho Pharmaceutical; Yakult Honsha